Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A071702||Alliance||A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0106||SWOG||A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) during Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated De Novo Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Completed|
|A031902||Alliance||CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1899||ECOG||Phase III Randomized Trial for Evaluating Second Line Hormonal Therapy (Ketoconazole/Hydrocortisone) versus Docetaxel/Estramustine Combination Chemotherapy on Progression Free Survival in Asymptomatic Patients with a Rising PSA after Hormonal Therapy for Prostate Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|AMC-111||AMC||Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living with HIV: A Feasibility Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|E5508||ECOG||Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0250||GOG||A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Bevacizumab (NSC #704865; IND #113912) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus. NCI Supplied Agent: Bevacizumab (NSC #704865; IND #113912) NCT#01012297||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-GY020||NRG||A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GI002||NRG||A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z4032||ACSOG||A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection Plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC); 3 cm or Smaller||Adult CIRB - Late Phase Emphasis||Completed|